Alternative Names
Eculizumab; soliris; 219685-50-4; h5G1.1; DB01257 C5; complement component 5; complement C5; CPAMD4; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; FLJ17816; FLJ17822; MGC142298;
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Its related pathways are Immune response Lectin induced complement pathway and Signaling by GPCR.
Related Pathways
1.C5 activated by C5 convertase initiates the spontaneous assembly of late complement components C5-c9 to form a membrane attack complex. C5b has a short-term binding site for C6. The C5b-C6 complex is the basis for the assembly of the cleavage complex. 2.C5 anaphylactic shock toxin is derived from the proteolytic degradation of complement C5 and is the mediator of the local inflammatory process. Binding to the receptor C5AR1 can cause a variety of reactions, including intracellular calcium release, smooth muscle contraction, increased vascular permeability, and histamine release from mast cells and basophils (PubMed:8182049). C5a is also a powerful chemokine, which stimulates the movement of polymorphonuclear leukocytes and guides them to migrate to the site of inflammation.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2 / G4, κ
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human C5. Eculizumab also is the first agent approved for the treatment of atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.
Indication
Neuromyelitis optica (NMO)
